Department of Dermatovenereology, 2nd Medical School Charles University and Bulovka Hospital, Prague, Czech Republic.
Dermatol Ther. 2012 Jan-Feb;25(1):95-7. doi: 10.1111/j.1529-8019.2012.01433.x.
The study describes the case of a patient with a clinical and histopathological diagnosis of pemphigus vulgaris accompanied by severe side-effects of combined immunosuppressive therapy, who achieved a remission of the disease with adalimumab. Pemphigus vulgaris is a chronic blistering disease of the skin and mucous membranes. Before corticosteroids were introduced, mortality was high. Corticosteroids are currently used as first-line therapy. To reduce the dose of corticosteroids, therapeutic combinations with corticosteroid-sparing immunosuppressive agents are used. The therapy brings a number of complications due to its side effects. To achieve a remission of the disease by treating our patient with combined immunosuppressives, we administered adalimumab and achieved a very good clinical response.
该研究描述了一例临床和组织病理学诊断为寻常型天疱疮的患者，该患者在接受联合免疫抑制治疗后出现严重副作用，但随后用阿达木单抗治疗后疾病得到缓解。寻常型天疱疮是一种慢性水疱性皮肤黏膜疾病。在皮质类固醇问世之前，死亡率很高。目前皮质类固醇被用作一线治疗药物。为了减少皮质类固醇的剂量，会与皮质类固醇保治疗的免疫抑制剂联合使用。由于其副作用，该治疗会带来许多并发症。为了通过联合免疫抑制剂治疗我们的患者来实现疾病缓解，我们给予阿达木单抗治疗，并获得了非常好的临床反应。
